公开(公告)号：US09446059B2

公开(公告)日：2016-09-20

申请号：US14919418

申请日：2015-10-21

Applicant: AbbVie Inc.

Inventor： Benoit Cardinal-David ,  Vincent S. Chan ,  Kassibla E. Dempah ,  Brian P. Enright ,  Rodger F. Henry ,  Raimundo Ho ,  Ye Huang ,  Alexander D. Huters ,  Russell C. Klix ,  Scott W. Krabbe ,  Philip R. Kym ,  Yanbin Lao ,  Xiaochun Lou ,  Sean E. Mackey ,  Mark A. Matulenko ,  Peter T. Mayer ,  Christopher P. Miller ,  James Stambuli ,  Eric A. Voight ,  Zhi Wang ,  Geoff G. Zhang ,  Valentino J. Stella

IPC: A61K31/661 ,  C07F9/06 ,  A61K31/6615

CPC classification number: C07F9/094 ,  A61K31/661 ,  A61K31/6615 ,  A61K45/06 ,  C07B2200/13 ,  C07C47/277 ,  C07C281/02 ,  C07C309/24 ,  C07F9/06 ,  A61K2300/00

Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.

Abstract translation: 本公开内容涉及（a）卡比多巴前药，（b）药物组合和包含卡比多巴前药和/或左旋多巴前药的组合物，和（c）治疗帕金森病和相关病症的方法，包括施用卡比多巴前药和 左旋多巴前药与帕金森病患者。